Personalized CMV prevention could cut infections in kidney transplant patients
NCT ID NCT05708508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways to prevent cytomegalovirus (CMV) infection in kidney transplant patients who already carry the virus. One approach gives antiviral drugs to everyone for 3 months, while the other uses immune system tests to decide who needs treatment. The goal is to see if the personalized method reduces infections in the first 6 months after transplant. About 144 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Rouen
RECRUITINGRouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can a new IV antiviral tame two stubborn viruses?
- A new drug combo may shield kidney transplant patients from a common viral threat
- Blood test could tailor CMV prevention after stem cell transplants
- Can 'Supercharged' donor cells beat viruses that drugs Can't?
- Transplant breakdown? new study checks organ fluid for hidden germs